|Bid||75.60 x 800|
|Ask||75.63 x 1100|
|Day's Range||74.48 - 76.23|
|52 Week Range||63.41 - 140.36|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||40.83|
|Earnings Date||Oct 30, 2020 - Nov 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||113.67|
Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.
It is hard to get excited after looking at Haemonetics' (NYSE:HAE) recent performance, when its stock has declined 26...
Haemonetics (HAE) delivered earnings and revenue surprises of 12.20% and 1.35%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?